Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cBMA aspirate (concentrated bone marrow aspirate) is an autologous cell therapy consisting of a concentrated mixture of bone marrow-derived cells, including mesenchymal stromal cells (MSCs) and hematopoietic progenitor cells. The therapy is prepared at the point of care by harvesting bone marrow from the patient's iliac crest and concentrating it using specialized devices such as Zimmer Biomet's BioCue or MarrowStim. It is primarily investigated for the treatment of critical limb ischemia (CLI) and the prevention of ischemic wound complications in patients undergoing below-knee amputation (BKA). The mechanism of action involves the promotion of angiogenesis and vasculogenesis in ischemic tissues through the paracrine signaling and differentiation potential of the concentrated progenitor cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cBMA aspirate.